Recursion Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 missed consensus on revenue and EPS: total revenue $7.7M vs. $12.0M expected, and GAAP EPS $(0.25) vs. $(0.21) expected. Revenue decline of 60% YoY was driven by the timing of milestone project phases with Roche/Genentech. Despite the top-line miss, the company significantly narrowed net loss YoY through aggressive cost-cutting, leading to a lowered FY26 cash operating expense guidance of <$375M (from <$390M).